Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Antinuclear antibody testing — misunderstood or misbegotten?

Nature Reviews Rheumatology volume 13, pages 495–502 (2017)Cite this article

Subjects

Abstract

Antinuclear antibodies (ANAs) are a diverse group of autoantibodies that recognize nuclear macromolecules and their complexes. ANAs represent key biomarkers in the evaluation of rheumatic diseases, most prominently systemic lupus erythematosus (SLE), and ANA testing is commonly performed in the clinical setting. In addition, ANA testing is now used to assess eligibility for participation in clinical trials of new therapeutic agents for SLE. ANAs can be assayed by various techniques, with the fluorescent ANA assay often viewed as the gold standard. Whereas a positive ANA test represents a classification criterion for SLE, up to 20–30% of the healthy population, depending on the assay used, is positive for an ANA, complicating the use of this test for diagnosis or the detection of preclinical autoimmunity. Furthermore, ANAs might be expressed in SLE less commonly than often thought. This Perspectives article discusses important questions about the use of ANA testing in both the clinical and research settings.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: IFA testing for identifying the presence of ANAs.

Similar content being viewed by others

References

  1. Tan, E. M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv. Immunol. 44, 93–151 (1989).

    Article  CAS  PubMed  Google Scholar 

  2. Kavanaugh, A., Tomar, R., Reveille, J., Solomon, D. H. & Homburger, H. A. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch. Pathol. Lab. Med. 124, 71–81 (2000).

    Article  CAS  PubMed  Google Scholar 

  3. Meroni, P. L. & Schur, P. H. ANA screening: an old test with new recommendations. Ann. Rheum. Dis. 69, 1420–1422 (2010).

    Article  CAS  PubMed  Google Scholar 

  4. Agmon-Levin, N. et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann. Rheum. Dis. 73, 17–23 (2014).

    Article  CAS  PubMed  Google Scholar 

  5. Solomon, D. H., Kavanaugh, A. J. & Schur, P. H. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 47, 434–444 (2002).

    Article  PubMed  Google Scholar 

  6. Tan, E. M. et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 40, 1601–1611 (1997).

    Article  CAS  PubMed  Google Scholar 

  7. Abeles, A. M. & Abeles, M. The clinical utility of a positive antinuclear antibody test result. Am. J. Med. 126, 342–348 (2013).

    Article  PubMed  Google Scholar 

  8. Chan, E. K. et al. Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus 25, 797–804 (2016).

    Article  CAS  PubMed  Google Scholar 

  9. Damoiseaux, J. et al. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Auto Immun. Highlights 7, 1 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Schulte-Pelkum, J., Fritzler, M. & Mahler, M. Latest update on the Ro/SS-A autoantibody system. Autoimmun. Rev. 8, 632–637 (2009).

    Article  CAS  PubMed  Google Scholar 

  11. Ghillani, P. et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: results of a multicentric study. Autoimmun. Rev. 10, 509–513 (2011).

    Article  CAS  PubMed  Google Scholar 

  12. Fredi, M. et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus 23, 672–677 (2014).

    Article  CAS  PubMed  Google Scholar 

  13. Viana, V. T., Durcan, L., Bonfa, E. & Elkon, K. B. Ribosomal P antibody: 30 years on the road. Lupus 26, 453–462 (2017).

    Article  CAS  PubMed  Google Scholar 

  14. Pisetsky, D. S. The translocation of nuclear molecules during inflammation and cell death. Antioxid. Redox Signal. 20, 1117–1125 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Vallin, H., Perers, A., Alm, G. V. & Ronnblom, L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J. Immunol. 163, 6306–6313 (1999).

    CAS  PubMed  Google Scholar 

  16. Hua, J., Kirou, K., Lee, C. & Crow, M. K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 54, 1906–1916 (2006).

    Article  CAS  PubMed  Google Scholar 

  17. Eloranta, M. L. et al. Regulation of the interferon-α production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 60, 2418–2427 (2009).

    Article  CAS  PubMed  Google Scholar 

  18. Kirou, K. A. et al. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52, 1491–1503 (2005).

    Article  CAS  PubMed  Google Scholar 

  19. Balboni, I. et al. Interferon-α induction and detection of anti-Ro, anti-La, anti-Sm, and anti-RNP autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. Arthritis Rheum. 65, 2424–2429 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hoffman, I. E. et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann. Rheum. Dis. 63, 1155–1158 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. To, C. H. & Petri, M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum. 52, 4003–4010 (2005).

    Article  CAS  PubMed  Google Scholar 

  22. Ching, K. H. et al. Two major autoantibody clusters in systemic lupus erythematosus. PLoS ONE 7, e32001 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gunnarsson, R., Hetlevik, S. O., Lilleby, V. & Molberg, O. Mixed connective tissue disease. Best Pract. Res. Clin. Rheumatol. 30, 95–111 (2016).

    Article  PubMed  Google Scholar 

  24. Gunawardena, H. The clinical features of myositis-associated autoantibodies: a review. Clin. Rev. Allergy Immunol. 52, 45–57 (2017).

    Article  CAS  PubMed  Google Scholar 

  25. Hepburn, A. L. The LE cell. Rheumatology (Oxford) 40, 826–827 (2001).

    Article  CAS  Google Scholar 

  26. Friou, G. J. Antinuclear antibodies: diagnostic significance and methods. Arthritis Rheum. 10, 151–159 (1967).

    Article  CAS  PubMed  Google Scholar 

  27. Fritzler, M. J. Choosing wisely: review and commentary on anti-nuclear antibody (ANA) testing. Autoimmun. Rev. 15, 272–280 (2016).

    Article  PubMed  Google Scholar 

  28. Wiik, A. S., Hoier-Madsen, M., Forslid, J., Charles, P. & Meyrowitsch, J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J. Autoimmun. 35, 276–290 (2010).

    Article  CAS  PubMed  Google Scholar 

  29. Russell, A. S. & Johnston, C. Relative value of commercial kits for ANA testing. Clin. Exp. Rheumatol. 21, 477–480 (2003).

    CAS  PubMed  Google Scholar 

  30. Gonzalez, D. A. et al. Autoantibody detection with indirect immunofluorescence on HEp-2 cells: starting serum dilutions for systemic rheumatic diseases. Immunol. Lett. 140, 30–35 (2011).

    Article  CAS  PubMed  Google Scholar 

  31. Copple, S. S. et al. Screening for IgG antinuclear autoantibodies by HEp-2 indirect fluorescent antibody assays and the need for standardization. Am. J. Clin. Pathol. 137, 825–830 (2012).

    Article  PubMed  Google Scholar 

  32. Abeles, A. M., Gomez-Ramirez, M., Abeles, M. & Honiden, S. Antinuclear antibody testing: discordance between commercial laboratories. Clin. Rheumatol. 35, 1713–1718 (2016).

    Article  PubMed  Google Scholar 

  33. Hahm, D. & Anderer, U. Establishment of HEp-2 cell preparation for automated analysis of ANA fluorescence pattern. Cytometry A 69, 178–181 (2006).

    Article  PubMed  Google Scholar 

  34. Bizzaro, N. et al. Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems. Autoimmun. Rev. 13, 292–298 (2014).

    Article  CAS  PubMed  Google Scholar 

  35. Krause, C. et al. EUROPattern Suite technology for computer-aided immunofluorescence microscopy in autoantibody diagnostics. Lupus 24, 516–529 (2015).

    Article  CAS  PubMed  Google Scholar 

  36. Fritzler, M. J. & Miller, B. J. Detection of autoantibodies to SS-A/Ro by indirect immunofluorescence using a transfected and overexpressed human 60 kD Ro autoantigen in HEp-2 cells. J. Clin. Lab. Anal. 9, 218–224 (1995).

    Article  CAS  PubMed  Google Scholar 

  37. Peene, I. et al. Sensitivity of the HEp-2000 substrate for the detection of anti-SSA/Ro60 antibodies. Clin. Rheumatol. 19, 291–295 (2000).

    Article  CAS  PubMed  Google Scholar 

  38. Hoffman, I. E., Peene, I., Veys, E. M. & De Keyser, F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin. Chem. 48, 2171–2176 (2002).

    Article  CAS  PubMed  Google Scholar 

  39. Mariz, H. A. et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 63, 191–200 (2011).

    Article  CAS  PubMed  Google Scholar 

  40. Satoh, M. et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 64, 2319–2327 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hilario, M. O. et al. Frequency of antinuclear antibodies in healthy children and adolescents. Clin. Pediatr. (Phila.) 43, 637–642 (2004).

    Article  Google Scholar 

  42. Olsen, N. J. et al. Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res. Ther. 14, R174 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Olsen, N. J. & Karp, D. R. Autoantibodies and SLE: the threshold for disease. Nat. Rev. Rheumatol. 10, 181–186 (2014).

    Article  PubMed  Google Scholar 

  44. Conrad, K., Rober, N., Andrade, L. E. & Mahler, M. The clinical relevance of anti-DFS70 autoantibodies. Clin. Rev. Allergy Immunol. 52, 202–216 (2017).

    Article  CAS  PubMed  Google Scholar 

  45. Gundin, S. et al. Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective. Auto Immun. Highlights 7, 10 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Wallace, D. J. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168–1178 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918–3930 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. van Vollenhoven, R. F. et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann. Rheum. Dis. 71, 1343–1349 (2012).

    Article  CAS  PubMed  Google Scholar 

  49. Petri, M. A. et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 65, 2143–2153 (2013).

    Article  CAS  PubMed  Google Scholar 

  50. Emlen, W. & O'Neill, L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 40, 1612–1618 (1997).

    Article  CAS  PubMed  Google Scholar 

  51. Sjowall, C. et al. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. J. Rheumatol. 35, 1994–2000 (2008).

    PubMed  Google Scholar 

  52. Gniewek, R. A., Stites, D. P., McHugh, T. M., Hilton, J. F. & Nakagawa, M. Comparison of antinuclear antibody testing methods: immunofluorescence assay versus enzyme immunoassay. Clin. Diagn. Lab. Immunol. 4, 185–188 (1997).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Tan, E. M. et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum. 42, 455–464 (1999).

    Article  CAS  PubMed  Google Scholar 

  54. Fritzler, M. J. et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. J. Rheumatol. 30, 2374–2381 (2003).

    CAS  PubMed  Google Scholar 

  55. Fenger, M. et al. Detection of antinuclear antibodies by solid-phase immunoassays and immunofluorescence analysis. Clin. Chem. 50, 2141–2147 (2004).

    Article  CAS  PubMed  Google Scholar 

  56. Op De Beeck, K. et al. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun. Rev. 10, 801–808 (2011).

    Article  CAS  PubMed  Google Scholar 

  57. Stearns, N. A., Zhou, S., Petri, M., Binder, S. R. & Pisetsky, D. S. The use of poly-L-lysine as a capture agent to enhance the detection of antinuclear antibodies by ELISA. PLoS ONE 11, e0161818 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Kavai, M., Bányai, A., Zsindely, A., Sonkoly, I. & Szegedi, G. Enzyme-linked immunosorbent assay for antibodies to native DNA in sera of patients with SLE. J. Immunol. Methods 48, 169–175 (1982).

    Article  CAS  PubMed  Google Scholar 

  59. Stokes, R. P., Cordwell, A. & Thompson, R. A. A simple, rapid ELISA method for the detection of DNA antibodies. J. Clin. Pathol. 35, 566–573 (1982).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Rubin, R. L., Joslin, F. G. & Tan, E. M. An improved ELISA for anti-native DNA by elimination of interference by anti-histone antibodies. J. Immunol. Methods 63, 359–366 (1983).

    Article  CAS  PubMed  Google Scholar 

  61. Sutjita, M., Hohmann, A., Boey, M. L. & Bradley, J. Microplate ELISA for detection of antibodies to DNA in patients with systemic lupus erythematosus: specificity and correlation with Farr radioimmunoassay. J. Clin. Lab. Anal. 3, 34–40 (1989).

    Article  CAS  PubMed  Google Scholar 

  62. Lopez-Longo, F. J. et al. Simultaneous identification of various antinuclear antibodies using an automated multiparameter line immunoassay system. Lupus 12, 623–629 (2003).

    Article  CAS  PubMed  Google Scholar 

  63. Damoiseaux, J., Boesten, K., Giesen, J., Austen, J. & Tervaert, J. W. Evaluation of a novel line-blot immunoassay for the detection of antibodies to extractable nuclear antigens. Ann. NY Acad. Sci. 1050, 340–347 (2005).

    Article  CAS  PubMed  Google Scholar 

  64. Shovman, O. et al. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann. NY Acad. Sci. 1050, 380–388 (2005).

    Article  CAS  PubMed  Google Scholar 

  65. Binder, S. R. Autoantibody detection using multiplex technologies. Lupus 15, 412–421 (2006).

    Article  CAS  PubMed  Google Scholar 

  66. Moder, K. G. et al. Measurement of antinuclear antibodies by multiplex immunoassay: a prospective, multicenter clinical evaluation. J. Rheumatol. 34, 978–986 (2007).

    CAS  PubMed  Google Scholar 

  67. Op De Beeck, K. et al. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun. Rev. 12, 137–143 (2012).

    Article  CAS  PubMed  Google Scholar 

  68. Tansley, S. L. & McHugh, N. J. Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies. Curr. Rheumatol. Rep. 16, 464 (2014).

    Article  PubMed  CAS  Google Scholar 

  69. Satoh, M., Tanaka, S. & Chan, E. K. The uses and misuses of multiplex autoantibody assays in systemic autoimmune rheumatic diseases. Front. Immunol. 6, 181 (2015).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  70. Robinson, W. H., Steinman, L. & Utz, P. J. Protein arrays for autoantibody profiling and fine-specificity mapping. Proteomics 3, 2077–2084 (2003).

    Article  CAS  PubMed  Google Scholar 

  71. Li, Q. Z. et al. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin. Exp. Immunol. 147, 60–70 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526–1533 (2003).

    Article  CAS  PubMed  Google Scholar 

  73. McClain, M. T. et al. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat. Med. 11, 85–89 (2005).

    Article  CAS  PubMed  Google Scholar 

  74. Lu, R. et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J. Autoimmun. 74, 182–193 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Munroe, M. E. et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann. Rheum. Dis. 75, 2014–2021 (2016).

    Article  CAS  PubMed  Google Scholar 

  76. Wandstrat, A. E. et al. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J. Autoimmun. 27, 153–160 (2006).

    Article  CAS  PubMed  Google Scholar 

  77. Mahler, M. et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J. Rheumatol. 39, 2104–2110 (2012).

    Article  PubMed  Google Scholar 

  78. Hahn, B. H. Antibodies to DNA. N. Engl. J. Med. 338, 1359–1368 (1998).

    Article  CAS  PubMed  Google Scholar 

  79. Pisetsky, D. S. Anti-DNA antibodies — quintessential biomarkers of SLE. Nat. Rev. Rheumatol. 12, 102–110 (2016).

    Article  CAS  PubMed  Google Scholar 

  80. Schur, P. H. & Sandson, J. Immunologic factors and clinical activity in systemic lupus erythematosus. N. Engl. J. Med. 278, 533–538 (1968).

    Article  CAS  PubMed  Google Scholar 

  81. Ward, M. M., Pisetsky, D. S. & Christenson, V. D. Antidouble stranded DNA antibody assays in systemic lupus erythematosus: correlations of longitudinal antibody measurements. J. Rheumatol. 16, 609–613 (1989).

    CAS  PubMed  Google Scholar 

  82. Neogi, T., Gladman, D. D., Ibanez, D. & Urowitz, M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J. Rheumatol. 33, 1785–1788 (2006).

    CAS  PubMed  Google Scholar 

  83. Biesen, R. et al. Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthritis Res. Ther. 13, R26 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Venner, A. A. et al. Comparison of three anti-dsDNA assays: performance and correlation with systemic lupus erythematosus disease activity. Clin. Biochem. 46, 317–320 (2013).

    Article  CAS  PubMed  Google Scholar 

  85. Bonroy, C., Verfaillie, C., De Witte, E. & De Keyser, F. Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Arthritis Rheumatol. 66, 479–480 (2014).

    Article  PubMed  Google Scholar 

  86. Enocsson, H. et al. Four anti-dsDNA antibody assays in relation to systemic lupus erythematosus disease specificity and activity. J. Rheumatol. 42, 817–825 (2015).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. USA; and at the Division of Rheumatology and Immunology, David S. Pisetsky is at Medical Research Service, Durham Veterans Administration Medical Center, Box 151G, 508 Fulton Street, Durham, North Carolina 27705, Duke University Medical Center, DUMC 3544, Durham, North Carolina 27710, USA.,

    David S. Pisetsky

  2. and at the Division of Rheumatology and Immunology, Duke University Medical Center, DUMC 3544, Durham, North Carolina 27710, USA.,

    David S. Pisetsky

Authors
  1. David S. Pisetsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David S. Pisetsky.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pisetsky, D. Antinuclear antibody testing — misunderstood or misbegotten?. Nat Rev Rheumatol 13, 495–502 (2017). https://doi.org/10.1038/nrrheum.2017.74

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2017.74

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research